FDA Approves Kebilidi for Aromatic L-Amino Acid Decarboxylase Deficiency

TUESDAY, Nov. 26, 2024-- The U.S. Food and Drug Administration has approved Kebilidi (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.The adeno-associated...